|
|
 |
|
Viewing report
|
|
|
|
South Korea Pharmaceuticals and Healthcare Report Q4 2008
Business Monitor International, Dec 2008, Pages: 97
South Korea Pharmaceuticals and Healthcare Report provides independent forecasts and competitive intelligence on South Korea's pharmaceuticals and healthcare industry.
South Korea’s US$14.75bn pharmaceutical market is one of the most promising in the world. High growth coupled with preference for branded goods makes it very attractive to multinational drugmakers and consumer healthcare companies. Through to 2012, BMI is projecting a compound annual growth rate (CAGR) of 8.56% in US$ terms.
In Q308, South Korean drugmakers were severely impacted by high oil and raw material prices, which doubled manufacturing and distribution costs in some instances. Companies specialising in liquid drugs were the most affected because distribution of these products typically costs more than solid preparations. The local South Korean pharmaceutical industry is relatively well developed, despite being mostly focused on generic products. South Korea has around 250 manufacturers, with leading companies including Dong-A Pharmaceutical, Daewoong, Yuhan, Choongwae and Hanmi. In recent years, local producers have turned their attention to R&D of novel drugs, in a bid to boost their position both at home and regionally.
Continuing the global trend, the use of healthcare economics in reimbursement decisions is becoming more frequent in South Korea. In June 2008, it was revealed that the Health Insurance Review and Assessment Service (HIRA) was collaborating with the UK’s National Institute for Clinical Excellence (NICE), which is arguably the most pragmatic medicine cost effective watchdog in the world.
We expect South Korea’s US$2.6bn over-the-counter (OTC) market to expand significantly over the next five years. Key drivers include sector liberalisation, an ageing population, the removal of certain prescription drugs from the reimbursement list, more sophisticated marketing campaigns and increased self-medication. By 2012, we are forecasting that annual sales of non-prescription drugs will reach US$2.8bn, which equates to per capita spending of US$56.
Every year, approximately 110,000 people in South Korea are diagnosed with cancer and 64,000 will die of it. The disease became the leading cause of death in 1983 and there are no signs that this will change in the medium term. Stomach, lung, liver and colorectal cancers are the most common malignant neoplasms in South Korean men, while stomach, breast, colorectal and cervical account for the most cases in females.
Product samples
A sample for this product is available. Please Login/Register to download this sample.
Customers who bought this item also bought
South Korea Pharmaceuticals and Healthcare Report Q1 2009
South Korea Pharmaceuticals and Healthcare Report Q2 2008
The Pharmaceutical Market: South Korea
OTC Pharmaceuticals in South Korea
Pharmaceuticals in South Korea
Pharmaceutical Industry in South Korea
OTC Healthcare in South Korea to 2010
South Korea Pharmaceuticals and Healthcare Report Q3 2008
Analgesics in South Korea
Eye Care in South Korea
Wound Treatments in South Korea
South Korea Pharmaceuticals and Healthcare Report Q4 2009
|
|
|
|
